Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Increasing Diversity in Clinical Trials: Overcoming Critical Barriers
Luther T. Clark, Laurence O. Watkins, Ileana L. Piña, et al.
Current Problems in Cardiology (2018) Vol. 44, Iss. 5, pp. 148-172
Open Access | Times Cited: 570

Showing 1-25 of 570 citing articles:

Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy
Bassel Nazha, Manoj K. Mishra, Rebecca D. Pentz, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 3-10
Closed Access | Times Cited: 222
Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England
Yen Yi Tan, Václav Papež, Wai Hoong Chang, et al.
The Lancet Healthy Longevity (2022) Vol. 3, Iss. 10, pp. e674-e689
Open Access | Times Cited: 137
Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action
Danielle H. Bodicoat, Ash Routen, Andrew Willis, et al.
Trials (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 132
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
Marcus Mall, Rossa Brugha, Silvia Gärtner, et al.
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 206, Iss. 11, pp. 1361-1369
Open Access | Times Cited: 88
Advancing the inclusion of underrepresented women in clinical research
Barbara E. Bierer, Laura Meloney, Hayat Ahmed, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 4, pp. 100553-100553
Open Access | Times Cited: 85
A Plea for Diversity in Eating Disorders Research
Georg Halbeisen, Gerrit Brandt, Georgios Paslakis
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 84
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 83
Applying mixed methods to pilot feasibility studies to inform intervention trials
Kelly A. Aschbrenner, Gina Kruse, Joseph J. Gallo, et al.
Pilot and Feasibility Studies (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 75
A systematic review of sociodemographic reporting and representation in eating disorder psychotherapy treatment trials in the United States
C. Blair Burnette, Jessica Luzier, Chantel M. Weisenmuller, et al.
International Journal of Eating Disorders (2022) Vol. 55, Iss. 4, pp. 423-454
Open Access | Times Cited: 73
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Patricia J. Rodriguez, Brianna M. Goodwin Cartwright, Samuel Gratzl, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 9, pp. 1056-1056
Open Access | Times Cited: 61
Using AI to measure Parkinson’s disease severity at home
Md. Saiful Islam, Wasifur Rahman, Abdelrahman Abdelkader, et al.
npj Digital Medicine (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 51
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
Ahmet Uluer, Gordon MacGregor, Pilar Azevedo, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 6, pp. 550-562
Open Access | Times Cited: 45
Designing an accessible and equitable conference and the evaluation of the barriers to research inclusion for rare disease communities
Andrew E. P. Mitchell, Sondra Butterworth
Community and Interculturality in Dialogue (2024) Vol. 4, pp. 106-106
Open Access | Times Cited: 29
Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
Igor Andrade Santos, Victória Riquena Grosche, Fernando R.G. Bergamini, et al.
Frontiers in Microbiology (2020) Vol. 11
Open Access | Times Cited: 101
Increasing Participation of Women in Cardiovascular Trials
Leslie Cho, Amanda R. Vest, Michelle L. O’Donoghue, et al.
Journal of the American College of Cardiology (2021) Vol. 78, Iss. 7, pp. 737-751
Open Access | Times Cited: 95
Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement
Erin D. Michos, Tina K. Reddy, Martha Gulati, et al.
American Journal of Preventive Cardiology (2021) Vol. 8, pp. 100250-100250
Open Access | Times Cited: 90
Addressing inequities in COVID-19 morbidity and mortality: research and policy recommendations
Monica L. Wang, Pamela Behrman, Akilah Dulin‐Keita, et al.
Translational Behavioral Medicine (2020) Vol. 10, Iss. 3, pp. 516-519
Open Access | Times Cited: 87
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria
Sanne Franzen, Jade Emily Smith, Esther van den Berg, et al.
Alzheimer s & Dementia (2021) Vol. 18, Iss. 4, pp. 810-823
Open Access | Times Cited: 87
Machine learning in pharmacometrics: Opportunities and challenges
Mason McComb, Robert R. Bies, Murali Ramanathan
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 4, pp. 1482-1499
Open Access | Times Cited: 86
Integrating Research into Community Practice — Toward Increased Diversity in Clinical Trials
Janet Woodcock, Richardae Araojo, Twyla Thompson, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1351-1353
Open Access | Times Cited: 83
Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials
Karen Allison, Deepkumar Patel, Leah Greene
JAMA Network Open (2021) Vol. 4, Iss. 5, pp. e218348-e218348
Open Access | Times Cited: 61
Recruitment of Black Adults into Cardiovascular Disease Trials
Anagha Prasanna, Hailey Miller, Yingfei Wu, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 17
Open Access | Times Cited: 61
Diversity in clinical trials: an opportunity and imperative for community engagement
Darrell M. Gray, Timiya S. Nolan, John Gregory, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 8, pp. 605-607
Open Access | Times Cited: 60
Modifiable Barriers for Recruitment and Retention of Older Adults Participants from Underrepresented Minorities in Alzheimer’s Disease Research
Khushnoo K. Indorewalla, Maureen K. O’Connor, Andrew E. Budson, et al.
Journal of Alzheimer s Disease (2021) Vol. 80, Iss. 3, pp. 927-940
Open Access | Times Cited: 59
Sex, Racial, and Ethnic Representation in COVID-19 Clinical Trials
Hong Xiao, Riha Vaidya, Fang Liu, et al.
JAMA Internal Medicine (2022) Vol. 183, Iss. 1, pp. 50-50
Open Access | Times Cited: 55
Page 1 - Next Page

Scroll to top